UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

___________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~February~~ 27March 18, 2019

ARCTURUS THERAPEUTICS LTD.

(Exact Name of Registrant as Specified in Charter)

State of Israel (State or Other Jurisdiction of Incorporation)	001-35932 (Commission File Number)		Not applicable (I.R.S. Employer Identification No.)
State of Israel(State or OtherJurisdiction ofIncorporation)	001-35932(Commission FileNumber)		46-1981974 (I.R.S. EmployerIdentification No.)
10628 Science Center Drive, Suite 250
San Diego, California		92121
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 900-2660

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

o☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).

o☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Item 7.01~~1

~~Regulation~~Item ~~FD Disclosure~~2.02

~~Arcturus~~Results ~~Therapeutics Ltd. (the “Company”) has made available a presentation about the Company’s business (the “Presentation”), a copy~~ of ~~which~~Operations ~~is filed as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”)~~ and isFinancial ~~hereby incorporated by reference~~Conditions.

~~The~~On ~~furnishing~~March of18, ~~the~~2019, ~~Presentation~~Arcturus isTherapeutics ~~not an admission as to the materiality of any information therein~~Ltd. ~~The information contained in~~ (the ~~Presentation is summary information that should be considered in the context of the~~ “Company’s” ~~filings~~or ~~with the Securities and Exchange Commission (the~~ “~~SEC~~Arcturus”) ~~and~~ ~~other~~issued ~~public~~a ~~announcements the Company may make by~~ press release, ora ~~otherwise~~copy ~~from~~of ~~time~~which tois ~~time.~~furnished ~~The~~herewith ~~Presentation speaks~~ as of ~~the~~Exhibit ~~date of this Report~~99.1, ~~While~~announcing the Company’s ~~may~~financial ~~elect~~results tofor ~~update~~ the ~~Presentation~~quarter inand ~~the~~year ~~future~~ended toDecember ~~reflect~~31, ~~events~~2018 and ~~circumstances occurring~~providing ora ~~existing~~corporate ~~after~~update (the ~~date~~“Press ~~of this Report, the Company specifically disclaims any obligation to do so~~Release”).

The ~~Presentation~~information ~~contains~~contained ~~forward~~in Item 2.02 of this Current Report on Form 8-~~looking statements~~K, ~~and~~including the Press Release attached hereto as Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) ~~result~~of the Securities Act of 1933, ~~investors~~as ~~should~~amended. In addition, this information shall not ~~place~~be ~~undue~~deemed ~~reliance~~incorporated onby ~~these~~reference ~~forward-looking~~into ~~statements~~any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

~~The~~Cautionary ~~information~~Note ~~set~~Regarding ~~forth~~Forward-Looking in this Item 7.01 or the Presentation is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.Statements

~~Cautionary~~Certain ~~Note~~statements ~~Regarding~~in ~~Forward~~this communication and the Press Release are forward-~~Looking~~looking ~~Statements~~statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995.

~~Certain~~The Press Release contains “forward-looking statements” inthat ~~this~~involve ~~communication~~substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, ~~including~~ other than statements ~~relating~~of tohistorical fact, included in the ~~Company’s~~Press ~~future~~Release ~~ownership,~~regarding ~~capitalization~~strategy, ~~listing~~future ~~status~~operations, collaborations, future financial ~~condition~~position, ~~performance~~prospects, ~~operating~~ ~~results~~plans and objectives of management, ~~strategy~~the ~~and~~likelihood ~~plans~~of ~~are~~success ~~“forward-looking~~of the Company’s technology or potential development of any products, including statements” ~~within~~relating to the ~~meaning~~status of the ~~Private~~preclinical ~~Securities Litigation~~development ~~Reform~~program ~~Act~~for ARCT-810 or the other clinical development programs of ~~1995~~Arcturus, ~~giving~~the date that an IND may be filed with the ~~Company’s~~FDA, ~~expectations~~the potential for ARCT-810 or ~~predictions~~the other clinical development programs of Arcturus, current standards of care, and the Company’s future ~~financial~~cash position are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions or ~~business~~meet ~~performance~~ the expectations or ~~conditions~~projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. ~~These~~Actual results and performance could differ materially from those projected in any forward-looking statements ~~are~~as ~~subject~~a result of many factors, including without limitation, an inability to ~~numerous~~develop ~~assumptions~~and market product candidates, inability to generate positive verifiable data, unexpected clinical results, unforeseen expenses and general market conditions that may prevent such achievement or performance. Such statements are based on management’s current expectations and involve risks and uncertainties, ~~which~~including ~~change~~those ~~over time.~~discussed ~~Forward~~under the heading “Risk Factors” in Arcturus’ Annual Report on Form 10-~~looking~~K ~~statements~~for ~~speak~~the ~~only~~fiscal asyear ofended December 31, 2018, filed with the ~~date~~SEC ~~they~~on ~~are~~March ~~made~~18, 2019 and in subsequent filings with, or submissions to, the ~~Company~~SEC. ~~assumes~~Except noas ~~duty~~otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, ~~except~~which speak only as ~~required~~of bythe ~~law~~date they were made, whether as a result of new information, future events or circumstances or otherwise.

InThe ~~addition~~statements tomade ~~factors~~in ~~previously~~this ~~disclosed in~~Current ~~the~~Report ~~Company’s~~on ~~reports~~Form ~~filed~~8-K ~~with~~and the ~~SEC~~exhibit(s) ~~and~~attached ~~those~~hereto ~~identified~~speak ~~elsewhere~~only inas ~~this~~of ~~communication,~~ the ~~following~~date ~~factors, among~~stated ~~others~~herein, ~~could cause actual results to differ materially from forward-looking statements~~ and ~~historical~~subsequent ~~performance:~~events ~~the availability~~ and ~~access,~~developments inmay ~~general,~~cause ofthe ~~funds~~Company’s toexpectations ~~fund operations~~ and ~~necessary~~beliefs ~~capital~~to ~~expenditures,~~change. While the ~~strength~~Company ofmay ~~our~~elect ~~intellectual~~to ~~property portfolio,~~update ~~the~~these ~~expected~~forward-looking ~~safety~~statements ~~profiles~~publicly ofat ~~our~~some ~~product~~point ~~candidates,~~in the ~~proof of concept of our product candidates~~future, the ~~target~~Company ~~opportunities for~~specifically ~~certain~~disclaims ofany ~~our~~obligation ~~product~~to ~~candidates~~do so, ~~our~~whether ~~expected~~as ~~dates~~a ofresult ~~submission~~ of ~~one~~new ~~or more Investigational New Drug Applications to the FDA~~information, ~~market~~future ~~opportunities~~events ~~with respect to certain diseases connected with our product candidates, manufacturing and formulation capabilities of the Company~~ or ~~our manufacturing partners with respect to our product candidates~~otherwise, asexcept ~~well~~ as ~~our~~required ~~management’s response~~by ~~to the preceding factors~~law. ~~The~~These ~~foregoing~~forward-looking ~~factors~~statements ~~are~~should innot ~~addition~~be torelied ~~the~~upon ~~other~~as ~~factors~~representing ~~set forth in~~ the Company’s ~~reports~~ onviews ~~Form~~as ~~20-F,~~of ~~Form~~any ~~6-K,~~date ~~and~~after ~~other~~the ~~documents~~date onstated ~~file with the SEC~~herein.

~~Other~~Item ~~risks and uncertainties are more fully described in the Company’s Annual Report on Form 20-F for the year ended December 31, 2017 and Amendment No~~9.01 1Financial ~~thereto,~~Statements ~~each filed with the SEC,~~ and ~~in other filings that the Company makes and will make with the SEC~~Exhibits. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The statements made in this Current Report on Form 8-K and the exhibit(s) attached hereto speak only as of the date stated herein, and subsequent events and developments may cause the Company’s expectations and beliefs to change. While the Company may elect to update these forward-looking statements publicly at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date stated herein.

~~Item~~Exhibit ~~9.01~~Number ~~Financial Statements and Exhibits.~~Description

	Exhibit Number	Description
	99.1	Presentation of Arcturus Therapeutics Ltd., dated February 2019

99.1 Press Release of Arcturus Therapeutics Ltd., dated March 18, 2019

~~SIGNATURES~~2

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~SIGNATURES

	ARCTURUS THERAPEUTICS LTD.
	By:	/s/ Joseph E. Payne
		Joseph E. Payne
		Chief Executive Officer
Dated: February 27, 2019

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ARCTURUS THERAPEUTICS LTD.


	By:	/s/ Joseph E. Payne
		Joseph E. Payne
		President, Chief Executive Officer and Director


Dated: March 18, 2019

Filing Compare · Arcturus Therapeutics Ltd.